L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Executive Insights Life Sciences & Pharma Is Biopharma Doing Enough to Advance Novel Targets? May 15, 2025
Executive Insights Healthcare The Race Is On: Winning Smart in the Intensifying GLP-1 Market in China May 15, 2025
Case Study Life Sciences & Pharma Global Manufacturing Footprint Rationalization for a Leading Biopharmaceutical Company March 31, 2025 A leading biopharmaceutical company engaged L.E.K. Consulting to optimize its global manufacturing network. The client sought to reduce costs while…
Smart Chart Life Sciences & Pharma Unlocking Growth: Singapore's Role in Advancing Life Sciences and Medtech Innovations March 10, 2025
Executive Insights Life Sciences & Pharma Redefining Biopharma R&D Productivity: New Insights and Strategies January 9, 2025
Executive Insights Healthcare Services The Evolution of Structured Weight Management Programs November 14, 2024
